LDLR and hyperlipidemia: Given these findings, vutiglabridin was tested in WD-fed LDLR−/− mice as a model of obesity and hyperlipidemia where we observed a significant reduction of body weight, fat mass, and cholesterol, that was coupled with a remarkable increase in PON1 plasma expression and activity.